Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results